Provide context on the base revenue and contribution margin of high-value subsegments like electronics and medical within Engineered Materials, and expected long-term growth rates.

Electronics represents about 10% of EM revenue but 10-15% of its contribution margin. Medical is less than 10% of revenue but about 20% of contribution margin. These segments are foundational and high-growth areas where Celanese aligns unique capabilities for differentiated opportunities and sustainable growth. “electronics, for example, today, that's about 10% of the revenue of the Engineered Materials business, but actually makes up about 10% to 15% of the contribution margin that we make in the business. Medical is less than 10% of the revenue, but about 20% of the contribution margin that we make.”

How confident is management in the $700M-$800M free cash flow guidance for 2026, and how have working capital dynamics changed?

Management is very confident in the $700M-$800M free cash flow range. Q2 saw $140M FCF despite a $200M working capital build-up. Year-to-date working capital use is almost $300M, but it is expected to normalize to neutral or slightly positive for the full year. This range is considered a baseline sustainable level, with further EM inventory reductions expected next year. “Not a lot has changed. We're very confident in the free cash flow range that we've put out there in the second quarter, $140 million of free cash flow is actually pretty good considering the amount of working capital we've built up in the quarter, almost $200 million use of cash in the quarter.”

Why were Acetyl Chain volumes flat year-over-year in Q2, given available capacity, low costs, and competitor outages?

The flat Acetyl Chain volumes were primarily due to mix effects. Destocking in the acetate tow part of the value chain offset gains seen in the vinyls chain. “a lot of it's mix. We've continued to see some destocking in the acetate tow part of the value chain. So that volume was lower on a year-over-year basis, which was kind of offsetting the gains that we saw in the vinyls chain.”

Celanese (CE) Q2 FY26 earnings call: guidance and Q&A

Q: How has the Acetyl Chain operating environment normalized, especially between Western and Eastern Hemispheres, and what are the implications for Q3 expectations?

Moderation in the Acetyl Chain was as expected, but Q2 saw a slight benefit from EM prebuying. Q3 will be lower due to accelerated Lanaken closure (inventory absorption hit) and a $10M reduction in Ibn Sina equity earnings. Asia spreads normalized to pre-war levels by mid-Q2, while Western margins remain constructive. “I wouldn't say that moderation has been any more acute than what we expected. I think what we have seen happen is just some changes a little bit in the environment. And we ended up getting a little bit more benefit in the second quarter than we had originally guided to.”

Earnings call· Jun 2026 (Q2 FY26)· Materials· Aug 5, 2026

Source: earnings call transcript

Executive summary

Celanese Q2 FY26 — Strong Free Cash Flow and Strategic Growth in Engineered Materials

Celanese demonstrated resilience in Q2 FY26, leveraging its global supply chain to navigate volatile markets and deliver strong free cash flow. Strategic focus on high-value subsegments in Engineered Materials and aggressive cost reduction initiatives are expected to drive future growth and deleveraging, despite some near-term inventory absorption and raw material headwinds. Management remains committed to its divestiture targets and long-term leverage goals.

Highlights

Acetyl Chain (AC) demonstrated strong resiliency and flexibility, leveraging its global production network to ensure reliable supply.
Engineered Materials (EM) adjusted EBIT is expected to grow at double-digit rates, closer to 15%, for FY26 despite significant headwinds.
Generated $140M in free cash flow in Q2 FY26, with confidence in achieving $700M-$800M for the full year.
Commitment to $1B divestiture target by end of 2027 remains firm, with $500M remaining and at least one deal expected by year-end FY26.
EM is successfully driving mix enrichment and penetration into high-value subsegments like data centers and medical, contributing significantly to margins.

Concerns

Ibn Sina equity earnings are expected to be $10M lower than anticipated for FY26, primarily impacting Q3.
Higher inventory absorption hit anticipated in H2 FY26 due to accelerated Lanaken plant closure and EM closures.
Raw material cost inflation in Engineered Materials is expected to flow through in Q3 FY26, potentially causing margin compression.
Acetate tow business continues to experience some destocking pressure in H2 FY26, though at a slower pace.

Guidance & targets

Category	Target	Timeline	Confidence
Adjusted EPS	$1.35-$1.75 high materiality	Q3 FY26	Medium
Free Cash Flow	$700M-$800M high materiality	FY26	High
Working Capital	Neutral to slightly positive medium materiality	FY26	Medium
Divestiture Target	$1B high materiality	By end of 2027 · FY27	High
Divestiture Announcement	At least one deal medium materiality	By end of this year · FY26	High
Net Debt	~$10B high materiality	End of FY26	High
Net Debt	~$9B high materiality	End of FY27	High
Net Debt to EBITDA	Cross 5x high materiality	FY26	High
Net Debt to EBITDA	Get to 4x high materiality	Next threshold	Medium
Net Debt to EBITDA	Around 3x high materiality	Long-term	High

Segment performance

Segment	Revenue	YoY	QoQ	Margin
Acetyl Chain (AC) Volumes were flat year-over-year in Q2 due to destocking in acetate tow offsetting gains in vinyls. The business is pivoting towards downstream derivatives for differentiation. The accelerated Lanaken plant closure will result in an inventory absorption hit in H2. Western Hemisphere Profitability: StrongAsia Margins: Normalized to pre-war levels by mid-Q2Inventory Absorption Hit: Higher in H2 FY26Ibn Sina Equity Earnings Impact: $10M lower for FY26 (hitting Q3)	—	Flat	—	—
Engineered Materials (EM) Adjusted EBIT is expected to grow significantly despite headwinds. The segment is focused on high-value subsegments like electronics and medical. Automotive volumes were down with builds, but offset by growth in other areas and electric drive unit penetration. Price increases in H2 Q2 helped offset rising raw material costs. Electronics Revenue: ~10% of EM revenueElectronics Contribution Margin: 10-15% of EM contribution marginMedical Revenue: <10% of EM revenueMedical Contribution Margin: ~20% of EM contribution marginAutomotive Volumes: Down a few percentage points YoYNon-Automotive Volumes: Up YoYTurnaround Expense: $15M (Q2 FY26)Inventory Absorption Hit (Nylon Optimization): $45M (start of FY26)Adjusted EBIT Loss (Micromax Divestiture): $35M (prior to this year)	—	—	—	Adjusted EBIT growth closer to 15% (FY26 expectation)

Deals & partnerships

Micromax Sale of Micromax business

The Micromax transaction was announced last year and closed earlier this year, contributing to the company's deleveraging efforts.

Risks & headwinds

Ibn Sina Equity Earnings Reduction FY26, primarily Q3

$10M lower for FY26

Mitigation:Plant is running again, expecting higher dividend in Q4.

Inventory Absorption Hit H2 FY26

Higher level in H2 FY26

Mitigation:Due to accelerated Lanaken plant closure and EM closures, expected to lead to a cleaner 2027 and cost benefits.

Raw Material Cost Inflation in Engineered Materials Q3 FY26

Expected to flow through in Q3 FY26

Mitigation:Price increases implemented in H2 Q2 to offset a chunk of the raw flow-through.

Acetate Tow Destocking H2 FY26

Expected to continue in H2 FY26

Mitigation:Pace has slowed considerably; cost actions taken, Lanaken closure for cleaner 2027.

Supply Chain Volatility Ongoing

Ongoing volatility

Mitigation:Leveraging global footprint and flexibility to provide reliability of supply.

What to watch in Q3 FY26

Divestiture Progress

By end of FY26

Current $500M remaining of $1B target

Target Announcement of at least one deal

Why it matters

Key to achieving deleveraging targets and optimizing the portfolio.

We are committed to the $1 billion target of divestitures by the end of 2027, Kevin. That hasn't wavered. We are about halfway there after the Micromax transaction we announced last year and closed earlier this year. We're working a portfolio of items of various sizes, to be honest with you, some smaller, some a little bit larger, and we believe a combination of those will get us that additional $500 million, and we're still very confident about announcing at least one deal by the end of this year.

Find out whether CE delivers this. Inve re-checks your case every morning.

Q&A highlights

How has the Acetyl Chain operating environment normalized, especially between Western and Eastern Hemispheres, and what are the implications for Q3 expectations?

Moderation in the Acetyl Chain was as expected, but Q2 saw a slight benefit from EM prebuying. Q3 will be lower due to accelerated Lanaken closure (inventory absorption hit) and a $10M reduction in Ibn Sina equity earnings. Asia spreads normalized to pre-war levels by mid-Q2, while Western margins remain constructive.

“I wouldn't say that moderation has been any more acute than what we expected. I think what we have seen happen is just some changes a little bit in the environment. And we ended up getting a little bit more benefit in the second quarter than we had originally guided to.”

asked by Patrick Cunningham · answered by Scott Richardson

3 min read 6 chapters

Detailed narrative

Acetyl Chain Performance and Market Dynamics

The Acetyl Chain (AC) demonstrated strong resilience and flexibility in Q2 FY26, leveraging its global production and supply chain network to ensure reliable supply, particularly in Europe. While Western Hemisphere margins remained constructive and above pre-war levels, Asian margins normalized to pre-war levels by mid-Q2.

The business continues its strategic pivot towards downstream derivatives, which offer greater differentiation and innovation opportunities, helping to maintain profitability despite broader macro challenges. Management noted an anticipated inventory absorption hit in H2 FY26 due to accelerated plant closures.

Engineered Materials Strategic Focus

The Engineered Materials (EM) business is actively reorienting its focus towards high-value subsegments, aligning its unique capabilities with specific end-market needs. Electronics, for example, accounts for approximately 10% of EM revenue but 10-15% of its contribution margin, while medical, though less than 10% of revenue, contributes about 20% of the segment's contribution margin.

This strategy prioritizes value over volume, particularly in the automotive sector, and aims for differentiated opportunities that promise long-term sustainable growth. The company is observing mix enrichment and successful penetration into areas like AI data centers, which present significant material opportunities.

Cost Reduction and Productivity Initiatives

Celanese is aggressively pursuing cost improvements and productivity enhancements across its operations. Key initiatives include the accelerated closure of the Lanaken plant in the Acetyl Chain and ongoing nylon optimization efforts, which are expected to yield significant cost savings. Partial benefits from these actions are anticipated in H2 FY26, with full realization projected for FY27.

Management has set a target of $80M-$100M in cost reductions for FY27, aiming to offset potential changes in business conditions and further strengthen the company's cost structure.

Free Cash Flow Generation and Capital Allocation

The company generated $140M in free cash flow during Q2 FY26, despite a $200M working capital build-up in the quarter. Management expressed high confidence in achieving its full-year FY26 free cash flow guidance of $700M-$800M, considering this a baseline sustainable level for future periods.

Working capital is expected to normalize to a neutral or slightly positive position for the full year. Celanese remains committed to its $1B divestiture target by the end of 2027, with $500M remaining, and expects to announce at least one deal by the end of FY26.

Deleveraging Strategy and Targets

Celanese is making consistent progress on its deleveraging strategy. The company projects net debt to be approximately $10B by the end of FY26 and $9B by the end of FY27. The long-term leverage target for the balance sheet is around 3x net debt to EBITDA.

For FY26, the company expects to cross 5x net debt to EBITDA, with the next interim threshold targeted at 4x. This deleveraging is supported by strong free cash flow generation and strategic divestitures.

Drug Delivery and Data Center Opportunities

Beyond GLP-1, Celanese is enthusiastic about broader trends in drug delivery, including patient monitoring, at-home health, and self-administering injectables. The company's growth projections and market size estimates for this area already account for the potential impact of GLP-1 pills. Additionally, the evolving technology roadmap for data centers, particularly AI data centers, presents significant opportunities for Celanese's materials in connectors, thermal management, and wire and cable applications, leveraging its technical capabilities and customer relationships.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.